Coronavirus disease 2019 vaccination in cancer patients
10.3760/cma.j.cn114015-20210709-00772
- VernacularTitle:癌症患者的新型冠状病毒肺炎疫苗接种
- Author:
Zhiqiang TONG
1
;
Yue XING
1
;
Shuai JIANG
1
;
Xiang LI
1
;
Mei DONG
1
Author Information
1. 哈尔滨医科大学附属肿瘤医院药学部，哈尔滨 150081
- Publication Type:Journal Article
- Keywords:
Carcinoma;
SARS-CoV-2;
Vaccination;
COVID-19 vaccines
- From:
Adverse Drug Reactions Journal
2021;23(7):352-356
- CountryChina
- Language:Chinese
-
Abstract:
Patients with cancer are at high risk for coronavirus disease 2019 (COVID-19). Institutions for disease control and prevention and cancer-related learned societies in many countries recommend prioritizing cancer patients for COVID-19 vaccines. All the COVID-19 vaccines currently approved for emergency use, including inactivated vaccines, mRNA vaccines, recombinant adenovirus vector-based vaccines, and recombinant protein subunit vaccines, can be applied in cancer patients. Cancer patients with stable disease can be vaccinated against COVID-19 at any time, while patients with advanced-stage cancer or undergoing anticancer therapy should decide on the timing of vaccination according to the specific situation such as treatment methods and cancer type, etc.. The benefits of COVID-19 vaccination in cancer patients may outweigh the risks, but the immune response rate may be lower in cancer patients, especially in patients with haematological malignancies, than in healthy individuals.
